#310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.

Key Takeaways Copied to clipboard!

• The TRAVERSE trial suggests that testosterone replacement therapy (TRT) in hypogonadal men does not increase the risk of prostate cancer diagnosis, with prostate cancer detection rates being similar between TRT and placebo groups.  Copied to clipboard!
• Prostate cancer cells that are more aggressive tend to rely less on traditional androgen receptor signaling, suggesting a complex relationship where lower androgen receptor activity may correlate with higher tumor aggressiveness.  Copied to clipboard!
• For men with low-grade prostate cancer (e.g., Gleason 3+3), continuing TRT is generally considered safe and beneficial for overall health, as there's no evidence that exogenous testosterone accelerates or propagates existing prostate cancer.  Copied to clipboard!

Segments Expand All Collapse All

TRAVERSE Trial Prostate Cancer Findings

Copied to clipboard!

(01:15:12)

• Key Takeaway: The TRAVERSE trial found no increased risk of prostate cancer diagnosis in hypogonadal men receiving testosterone replacement therapy compared to placebo.
• Summary: This segment focuses on the secondary analysis of the TRAVERSE trial regarding prostate cancer. It details the study’s design, the low-risk profile of the participants (low PSA, hypogonadal), and the finding that testosterone supplementation did not lead to a higher incidence of prostate cancer detection. The discussion also touches on the characteristics of men who were diagnosed with prostate cancer within the trial, noting they had higher PSAs and PSA shifts.

Androgen Receptor Saturation Theory

Copied to clipboard!

(10:36:04)

• Key Takeaway: The androgen receptor saturation theory suggests that beyond certain serum testosterone levels (around 200-250 ng/mL for the prostate), additional testosterone provides diminishing returns for prostate tissue and hair follicles.
• Summary: This part of the conversation delves into the ‘saturation theory’ of androgen receptors. It explains how testosterone and DHT interact with receptors, leading to gene expression. The theory posits that end organs like the prostate and hair follicles reach saturation at relatively low testosterone levels, meaning higher levels don’t significantly increase the effect on these tissues, unlike muscle tissue which requires much higher levels for anabolic effects.

Androgen Receptor Activity in Prostate Cancer

Copied to clipboard!

(17:02:44)

• Key Takeaway: More aggressive prostate cancers exhibit lower androgen receptor (AR) signaling, suggesting they rely on alternative growth pathways and are less dependent on traditional androgen stimulation.
• Summary: The discussion shifts to the molecular characteristics of prostate cancer, referencing an early study that linked lower testosterone to higher-grade cancer. The speakers elaborate on their research developing an ‘androgen receptor activity signature’ (ARA score) which analyzes gene expression in prostate tumors. They found that tumors with less AR signaling are often more aggressive and have different vulnerabilities, contrasting with well-differentiated tumors that show high AR activity.

TRT and Prostate Cancer Management

Copied to clipboard!

(31:20:60)

• Key Takeaway: For men with low-grade prostate cancer, continuing testosterone replacement therapy is generally safe and recommended for overall health, as it does not appear to accelerate cancer progression.
• Summary: This segment addresses the practical implications of TRT for patients with prostate cancer. The speakers argue that for men with low-grade cancer (e.g., Gleason 3+3) who are on TRT, there’s no need to stop it, as it doesn’t worsen the cancer and contributes to their overall well-being. They differentiate this from higher-grade cancers where treatment decisions, particularly regarding androgen deprivation therapy alongside radiation, are more complex and influenced by molecular profiling.